دورية أكاديمية
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
| العنوان: | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. |
|---|---|
| المؤلفون: | Schmidt, MK, Hogervorst, F, van Hien, R, Cornelissen, S, Broeks, A, Adank, MA, Meijers, H, Waisfisz, Q, Hollestelle, A, Schutte, M, van den Ouweland, A, Hooning, M, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Antoniou, AC, Arndt, V, Bermisheva, M, Bogdanova, NV, Bolla, MK, Brauch, H, Brenner, H, Brüning, T, Burwinkel, B, Chang-Claude, J, Chenevix-Trench, G, Couch, FJ, Cox, A, Cross, SS, Czene, K, Dunning, AM, Fasching, PA, Figueroa, J, Fletcher, O, Flyger, H, Galle, E, García-Closas, M, Giles, GG, Haeberle, L, Hall, P, Hillemanns, P, Hopper, JL, Jakubowska, A, John, EM, Jones, M, Khusnutdinova, E, Knight, JA, Kosma, V-M, Kristensen, V, Lee, A, Lindblom, A, Lubinski, J, Mannermaa, A, Margolin, S, Meindl, A, Milne, RL, Muranen, TA, Newcomb, PA, Offit, K, Park-Simon, T-W, Peto, J, Pharoah, PDP, Robson, M, Rudolph, A, Sawyer, EJ, Schmutzler, RK, Seynaeve, C, Soens, J, Southey, MC, Spurdle, AB, Surowy, H, Swerdlow, A, Tollenaar, RAEM, Tomlinson, I, Trentham-Dietz, A, Vachon, C, Wang, Q, Whittemore, AS, Ziogas, A, van der Kolk, L, Nevanlinna, H, Dörk, T, Bojesen, S, Easton, DF |
| المساهمون: | Fletcher, Olivia, Jones, Michael, Swerdlow, Anthony |
| بيانات النشر: | LIPPINCOTT WILLIAMS & WILKINS |
| سنة النشر: | 2019 |
| المجموعة: | The Institute of Cancer Research (ICR): Publications Repository |
| مصطلحات موضوعية: | Humans, Breast Neoplasms, Genetic Predisposition to Disease, Receptors, Estrogen, Progesterone, Odds Ratio, Risk Assessment, Case-Control Studies, Age Factors, Sequence Deletion, Heterozygote, Homozygote, Adult, Aged, 80 and over, Middle Aged, Female, Checkpoint Kinase 2 |
| الوصف: | PURPOSE: CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. PATIENTS AND METHODS: CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies. RESULTS: Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center-based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 × 10(-20)). The OR was higher for estrogen receptor (ER)-positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 × 10(-21)]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 × 10(-4)). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom. CONCLUSION: These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print-Electronic; 2760; application/pdf |
| اللغة: | English |
| تدمد: | 0732-183X 1527-7755 |
| العلاقة: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34 (23), pp. 2750 - 2760; https://repository.icr.ac.uk/handle/internal/3013Test |
| DOI: | 10.1200/jco.2016.66.5844 |
| الإتاحة: | https://doi.org/10.1200/jco.2016.66.5844Test https://repository.icr.ac.uk/handle/internal/3013Test |
| حقوق: | https://www.rioxx.net/licenses/all-rights-reservedTest |
| رقم الانضمام: | edsbas.9E5FF118 |
| قاعدة البيانات: | BASE |
| تدمد: | 0732183X 15277755 |
|---|---|
| DOI: | 10.1200/jco.2016.66.5844 |